Two Sigma Investments
MLTX icon

Two Sigma Investments’s MoonLake Immunotherapeutics MLTX Stock Holding History

Two Sigma Investments’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20.9M Buy
1,122,312
+337,501
+43% +$5.59M 0.02% 918
2025
Q4 		$10.3M Buy
784,811
+330,543
+73% +$3.9M 0.01% 1099
2025
Q3 		$3.26M Buy
+454,268
New +$23.7M ﹤0.01% 1791
2025
Q2 		– Sell
-35,638
Closed -$1.39M – 3393
2025
Q1 		$1.39M Buy
+35,638
New +$1.54M ﹤0.01% 1975
2024
Q1 		– Sell
-3,853
Closed -$233K – 3242
2023
Q4 		$233K Hold
3,853
– – ﹤0.01% 2774
2023
Q3 		$220K Buy
+3,853
New +$213K ﹤0.01% 2603
2023
Q1 		– Sell
-12,385
Closed -$130K – 3108
2022
Q4 		$130K Buy
+12,385
New +$110K ﹤0.01% 2471

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Two Sigma Investments's MLTX Position: Q1 2026 in Review

Two Sigma Investments increased its MoonLake Immunotherapeutics (MLTX) stake by 43% in Q1 2026, buying an estimated $5.59M and bringing the position to 1,122,312 shares worth $20.9M. The position accounts for 0.02% of the portfolio, ranked #918.

Two Sigma Investments first reported a position in MLTX in Q4 2022 and has held it in 7 quarters since. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

  • Two Sigma Investments held 1,122,312 shares of MoonLake Immunotherapeutics worth $20.9M as of Q1 2026.
  • Two Sigma Investments bought 337,501 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $5.59M.
  • MoonLake Immunotherapeutics made up 0.02% of Two Sigma Investments's portfolio in Q1 2026, its #918 holding.
  • Two Sigma Investments first reported a position in MoonLake Immunotherapeutics in Q4 2022 and has held it in 7 quarters since.
  • 147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.